We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Guidance Details Postmarket Studies Drugmakers May Be Asked to Perform
EMA Guidance Details Postmarket Studies Drugmakers May Be Asked to Perform
July 10, 2013
The European Medicines Agency June 17 issued updated guidance on postmarketing authorization measures (PAM), spelling out five types of postapproval studies the agency may specify during review of a marketing authorization application.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor